Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patients by unknown
Depincé‑Berger et al. Retrovirology  (2016) 13:44 
DOI 10.1186/s12977‑016‑0278‑5
RESEARCH
Major influence of CD4 count at the 
initiation of cART on viral and immunological 
reservoir constitution in HIV‑1 infected patients
Anne‑Emmanuelle Depincé‑Berger1,2†, Delphine Vergnon‑Miszczycha1,3†, Alexandre Girard1, Anne Frésard3, 
Elisabeth Botelho‑Nevers1,3, Claude Lambert1,2, Emilie Del Tedesco4, Christian Genin1,2, Bruno Pozzetto1,5, 
Frédéric Lucht1,3, Xavier Roblin1,4, Thomas Bourlet1,5*† and Stéphane Paul1,2†
Abstract 
Background: A persistent immune activation is observed in gut during HIV‑1 infection, which is not completely 
reversed by a combined antiretroviral therapy (cART). The impact of the time of cART initiation may highly influence 
the size of the viral reservoir and the ratio of CD4+/CD8+ T cells in the gut. In this study, we analyzed the characteris‑
tics of HIV rectal reservoir of long‑term treated patients, regarding their blood CD4+ T cells count at the time of cART 
initiation.
Results: Twenty‑four consenting men were enrolled: 9 exhibiting a CD4+ T cells count >350/mm3 (“high‑level CD4 
group”) and 15 < 350/mm3 (“low‑level CD4 group”) in blood, at the start of cART. An immunophenotypical analysis of 
T and B cells subpopulations was performed in blood and rectal biopsies. HIV cell‑associated DNA loads and quali‑
tative intra‑cellular RNA were determined in both compartments. The ratio of CD4+/CD8+ T cells was significantly 
decreased in the blood but not in the rectum of the “low‑level CD4 group” of patients. The alteration in β7+ CD4+ T 
cells homing was higher in this group and was correlated to a low ratio of CD4+/CD8+ T cells in blood. An initiation of 
cART in men exhibiting a low‑level CD4 count was also associated with an alteration of B cells maturation. HIV blood 
and gut DNA reservoirs were significantly lower in the “high‑level CD4 group” of men. A high HIV DNA level was asso‑
ciated to a detectable intracellular HIV RNA in rectum.
Conclusions: An early initiation of cART could significantly preserve gut immunity and limit the viral reservoir 
constitution.
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Background
Although combined antiretroviral therapy (cART) has 
dramatically improved the quality of life and lifespan of 
HIV infected individuals, it still fails to eliminate viral 
reservoirs. The Gut Associated Lymphoid Tissue (GALT) 
is the largest reservoir of HIV-1, as it harbors most of 
HIV target cells as activated memory CD4+/CCR5+ T 
cells [1, 2]. Intestinal T and B cells express α4β7 integ-
rin, a gut mucosal homing receptor which binds to gp120 
HIV-1 envelope, facilitating the infection of intestinal T 
cells and the early establishment of the gut HIV reservoir 
[3]. Intensive viral replication in the GALT leads to an 
early impairment of mucosal immunity, due to the severe 
CD4+ T cells depletion, that could also be explained by a 
lack of recruitment in the gut [4, 5]. Among T cells, IL-17 
secreting CD4+ T cells (Th17) are particularly depleted 
during HIV infection [6]. This depletion could be associ-
ated with HIV progression since these cells play a crucial 
role in the maintenance of mucosal immunity [6]. This 
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proinflammatory activity is balanced by regulatory T 
cells (Treg) and a dysbalance of the Th17/Treg ratio may 
reflect the loss of the intestinal epithelial barrier integ-
rity [7, 8]. During HIV infection, Treg cells are highly 
recruited into the GALT, which increase the imbalance 
with Th17 cells [9]. These damages are responsible for an 
increase in microbial translocation, which is associated 
with immune activation and progression to AIDS [10–
14]. B cells compartment has been poorly studied but 
it seems to be affected very early during HIV infection, 
with a global hyperactivity, partially reversed by cART 
[15, 16]. However, the influence of cART on B cells res-
cue remains unknown [15].
Several recent studies have shown that cART initia-
tion during acute or early HIV-1 infection reduces HIV 
DNA reservoir size and improves the ratio of CD4+/
CD8+ T cells in blood [17–20]. Post-treatment control-
lers (PTc), who started long-term cART early after HIV 
infection, have very low levels of HIV DNA in peripheral 
blood mononuclear cells (PBMC), similarly to elite con-
trollers [21]. Unlike most HIV-infected individuals, they 
maintain an undetectable plasmatic viral load after sev-
eral years of cART interruption, suggesting that a weak 
reservoir is a prerequisite to achieve a functional cure 
[21]. By extrapolation, it could be hypothesized that the 
gut viral reservoir is also decreased and that mucosal 
immunity is restored when cART is initiated during the 
primary phase of infection. In a monkey lab model, the 
initiation of suppressive cART 3 days after the infection 
blocked the emergence of viral RNA and proviral DNA 
in blood and reduced the size of viral reservoir in lymph 
nodes and GALT [22].
The gut viral reservoir begins to form within the first 
days after HIV exposure, and grows during acute HIV 
infection [23]. Similarly, intestinal T cells are depleted 
directly after infection [5], due to high viral replication, 
host immune response and bystander effects [24]. Most 
studies also concluded that long-term and optimal treat-
ment can’t fully restore mucosal immunity [25]. These 
observations led us to study the impact of time of cART 
start on the size of viral reservoir and on the ratio of 
CD4+/CD8+ T cells in the gut. For this, we analyzed the 
virological and immunological characteristics of the rec-
tal HIV reservoir of long-term treated patients, regard-
ing their blood CD4+ T cells count at the time of cART 
initiation.
Results
Twenty-four men were enrolled between May 2013 and 
March 2015. For 9 patients (“high-level CD4 group”), 
cART was initiated when the number of CD4+ T cells 
was over 350 CD4+ T cells/mm3 [398–1025/mm3]. For 
15 (“low-level CD4 group”), cART was initiated when the 
number of CD4+ T cells was below 350 CD4+ T cells/
mm3 [14–347/mm3]. The number of 350 CD4+ T cells/
mm3 was considered, since it has been suggested that 
mortality and disease progression is reduced if cART is 
started in patients exhibiting blood CD4+ T cells load 
above this threshold [26]. The cART was initiated during 
primary HIV infection (PHI, Fiebig III score [27]) in four 
patients, three belonging to “high-level CD4 group”, and 
one to “low-level CD4 group”. Detailed results of their 
immunophenotypical and virological markers are shown 
in Table 1.
Initiation of cART with high level of CD4 is associated 
with an elevation of the ratio CD4+/CD8+ T cells in blood 
but not in GALT (Fig. 1 and Additional file 1: Figure S1 
and Additional file 2: Fig. S2)
Overall, the ratio CD4+/CD8+ T cells was significantly 
higher in blood than in rectum (0.8 [0.5–1.1] vs 0.4 
[0.2–0.6], p = 0.0023). In blood, it was significantly corre-
lated to the CD4+ T cells count at the initiation of cART 
(r = 0.48, p = 0.02) (Fig. 1a1), but not in rectum (r = 0.28, 
p = 0.21). The exhausted/hyperactivated phenotype of T 
cells (PD1+) was higher in the rectum than in the blood 
(MFI of the gated CD4+/PD1+ population 35.9 [23.1–
51.4] vs 16.9 [16.2–17.8], p < 0.0001 and MFI of the gated 
CD8+/PD1+ population 29.4 [25.9–41.6] vs 17.7 [17.1–
27.9], p = 0.002; Fig. 1c–e) and was not significantly dif-
ferent between the two groups (MFI of CD3+/PD1+ T 
cells 17.8 [16.9–28] vs 17.7 [16.5–22], p = 0.79 in blood 
and MFI 30.9 [23.9–52.2] vs 38.8 [27.5–44.6], p  =  0.88 
in rectum). The proportion of p24+CD4+ T cells (among 
CD4+ T cells) was not significantly different between 
the 2 groups, in both compartments (0.71 % [0.26–1.45] 
in “high-level CD4 group” vs 0.92 % [0.39–1.59] in “low-
level CD4 group”, p =  0.55, in blood and 8.62  % [2.97–
16.72] in “high-level CD4 group” vs 7.23 % [2.42–27.46] 
in “low-level CD4 group”, p = 0.96, in rectum). The same 
findings were observed for the expression of CXCR4 co-
receptor (MFI CXCR4 17.78 [15.03–24] in “high-level 
CD4 group” vs 17.33 [16.69–21.74] in “low-level CD4 
group”, p = 0.72, in blood and MFI CXCR4 17.44 [15.42–
19.13] in “high-level CD4 group” vs 16.15 [16.02–18.61] 
in “low-level CD4 group”, p  =  0.46, in rectum) and for 
the expression of CCR5 co-receptor (MFI CCR5 42.03 
[37.82–46.63] in “high-level CD4 group” vs 40.75 [38.47–
46.23] in “low-level CD4 group”, p =  0.97, in blood and 
MFI CCR5 51.01 [43.41–65.4] in “high-level CD4 group” 
vs 52.64 [45.02–74.96] in “low-level CD4 group”, p = 1, in 
rectum). There was no difference of CXCR4 expression 
in CD4+ T cells between the two compartments (MFI 
CXCR4 17.39 [16.43–20.92] in blood vs 16.44 [16.02–
18.99] in rectum, p  =  0.27), whereas the expression of 
CCR5 co-receptor in CD4+ T cells was significantly 
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Table 1 Main results of immunophenotypical and virological reservoir analysis of patients enrolled in the study accord-
ing to their CD4+ cells count at the time of cART initiation
Medians of MFI or percentages [range]
CM central memory, EM effector memory, EMRA effector memory T cells expressing RA
Blood CD4+ T count at the time of diagnosis (cells/mm3) p value
>350 “high-level CD4 group” (n = 9) <350 “low-level CD4 group” (n = 15)
Immunophenotypical analysis of T cells
 MFI CD3+/PD1+ T cells
  Blood 17.8 [16.9–28] 17.7 [16.5–22] 0.79
  Rectum 30.9 [23.9–52.2] 38.8 [27.5–44.6] 0.88
 p24+/CD4+ T cells (% of CD4+ T cells)
  Blood 0.71 [0.26–1.45] 0.92 [0.39–1.59] 0.55
  Rectum 8.62 [2.97–16.72] 7.23 [2.42–27.46] 0.96
 MFI CXCR4 in CD4+ T cells
  Blood 17.78 [15.03–24] 17.33 [16.69–21.74] 0.72
  Rectum 17.44 [15.42–19.13] 16.15 [16.02–18.61] 0.46
 MFI CCR5 in CD4+ T cells
  Blood 42.03 [37.82–46.63] 40.75 [38.47–46.23] 0.97
  Rectum 51.01 [43.41–65.4] 52.64 [45.02–74.96] 1
 Th17 cells/Treg ratio
  Blood 2.9 [1.4–4.3] 2.2 [1.5–3] 0.64
  Rectum 1.4 [1.1–2.8] 1.3 [1.1–2.5] 0.96
 Blood/rectum ratio of β7+ expression in CD4+ T cells 0.9 [0.8–1.2] 1.6 [1.3–1.8] 0.0006
 Blood/rectum ratio of β7+ expression in CD8+ T cells 0.7 [0.5–1.2] 0.8 [0.7–1] 0.54
 MFI CCR9 in CD4+ T cells
  Blood 9.67 [9.29–10.65] 10.13 [9.27–11.25] 0.6
  Rectum 18.19 [13.93–23.51] 20.02 [16.05–25.23] 0.6
 MFI CCR9 in CD8+ T cells
  Blood 14.03 [13.01–20.02] 13.73 [13.19–17.29] 0.82
  Rectum 19.11 [16.41–24.14] 16.36 [14.78–18.78] 0.12
 Naive CD4+ T cells (% of CD4+ T cells)
  Blood 33.48 [27.55–46] 28.63 [17.03–42.8] 0.36
  Rectum 5.07 [1.96–10.35] 4.99 [3.54–7.12] 0.73
 CM CD4+ T cells (% of CD4+ T cells)
  Blood 38.29 [31.37–44.25] 37.06 [26.74–48.41] 0.97
  Rectum 24.38 [21.39–41.73] 15.42 [12.75–41.48] 0.39
 EM CD4+ T cells (% of CD4+ T cells)
  Blood 23.83 [11.89–27.31] 22.59 [12.78–33.74] 0.55
  Rectum 66.27 [53.45–71.44] 67.99 [50.44–82.32] 0.49
 EMRA CD4+ T cells (% of CD4+ T cells)
  Blood 4.83 [1.73–8.08] 2.23 [0.55–4.53] 0.22
  Rectum 0.61 [0.45–1.77] 0.39 [0.12–5.2] 0.66
Immunophenotypical analysis of B cells
 Blood naive IgD+ B cells (% of conventional B cells) 76.6 [60.6–79.1] 82.2 [77.3–87.6] 0.05
 Blood activated IgD− B cells (% of conventional B cells) 23.1 [20.8–38.8] 17.6 [12.4–22.4] 0.05
 Memory B cells (% of conventional B cells) 5.94 [1.68–18.05] 4.05 [2.07–5.66] 0.34
Virological reservoir analysis
 HIV DNA load (log10 copies/millions of cells)
  Blood 2.41 [2.03–2.93] 3.48 [3.17–3.7] 0.01
  Rectum 3.06 [1.93–3.63] 3.6 [3.4–4.08] 0.04
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higher in rectum (MFI CCR5 40.85 [37.9–45.91] in blood 
vs 52.64 [44.4–70.3] in rectum, p = 0.0006).
A persistent imbalance of the Th17/Treg ratio is maintained 
despite a higher level of CD4 when initiating cART (Fig. 1 
and Additional file 1: Figure S1)
The Th17 cells/Treg ratio was not different between the 
two groups of patients in blood (2.9 [1.4–4.3] in “high-
level CD4 group” and 2.2 [1.5–3] in “low-level CD4 
group”, p =  0.64) and in rectum (1.4 [1.1–2.8] in “high-
level CD4 group” and 1.3 [1.1–2.5] in “low-level CD4 
group”, p =  0.96). It tended to be associated to a lower 
exhaustion stage of CD8+T cells in blood (r  =  −0.48, 
p = 0.06; Fig. 1b).
Alterations in β7+CD4+ T cells homing to the gut is higher 
in patients who started cART with low CD4 count (Fig. 2 
and Additional file 3: Figure S3 and Additional file 4: Fig. 
S4)
The blood/rectum ratio of β7+ expression (MFI ratio 
from the gated CD4+/β7+ population) reflecting an 
approach to the alteration of gut homing, was calcu-
lated. It was significantly higher in patients who started 
the cART with low CD4 count (1.6 [1.3–1.8] vs 0.9 
[0.8–1.2], p = 0.006). An inverse correlation between the 
CD4 level at the time of cART initiation and the altera-
tion of β7+CD4+ T cells homing to the gut (r  =  −0.8, 
p =  0.0003) was observed (Fig.  2a). Nevertheless, there 
was no alteration of the gut homing of β7+/CD8+ T 
Fig. 1 Initiation of cART with higher CD4 level preserves CD4+ T cells in blood and exhaustion marker PD‑1 reveals a defect of the gut barrier integ‑
rity. Correlation between CD4+ T cells at the initiation of cART and ratio CD4+/CD8+ T cells in blood (a1) or with absolute numbers of CD4
+ T cells in 
blood (a2) and rectum (a3) or CD8
+ T cells (a4, a5). Correlation between PD‑1 expression on CD8
+ T cells (MFI) in blood and Th17/Treg ratio in blood 
(b). Differences of PD‑1 expression (MFI) in CD4+ and CD8 + T cells in blood and rectum (c, d). Flow cytometry analysis of this marker in CD4+ and 
CD8+ T cells (e). Gating strategy: lymphoid cells were gated using the FSC/SSC parameters. Then, T cells were gated by their expression of CD3 and 
were separated in CD4+ and CD8+ T cells by the CD4 expression and PD1 expression was studied in CD3+/CD4+ and CD3+/CD8+ T cells. Horizontal 
lines represent median values and ranges. *p < 0.05; ***p < 0.0001. Each symbol represents an individual patient
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cells (ratio 0.7 in “high-level CD4 group” [0.5–1.2] vs 0.8 
[0.7–1] in “low-level CD4 group”, p =  0.54). The altera-
tion of homing to the gut could also be evaluated also by 
the ratio of β7 expression in CD3+ T cells in blood and 
total CD3+ T cells in rectum but there was no difference 
between the two groups. The blood/rectum ratio of β7+/
CD4+ T cells was conversely associated with the ratio 
CD4+/CD8+ T cells in the blood (r = −0.51, p =  0.05) 
(Fig. 2b) but not in the rectum (r = 0.14, p = 0.61). CCR9 
gut homing receptor was expressed equally in both com-
partments (gut and blood) in the two groups. Its expres-
sion in rectal CD8+ T cells was not significantly higher 
in “high-level CD4 group” (MFI 19.11 [16.41–26.14]) 
versus “low-level CD4 group” (MFI 16.36 [14.78–18.78]), 
p  =  0.12. Overall, CCR9 expression in other subtypes 
(rectal and peripheral CD4+ T cells and peripheral CD8+ 
T cells) was similar in the two groups of patients (p > 0.5).
Among CD4+ T cells, no difference of distribution 
was observed in the subtypes of maturation according to 
the patient’s group (naive in blood, p = 0.36, and in gut, 
p = 0.73; CM in blood, p = 0.97 and in gut, p = 0.39; EM 
in blood, p = 0.55 and in gut, p = 0.49; EMRA, p = 0.22 
and in gut, p = 0.66).
CD4 low count at the initiation of cART leads to an 
alteration of B cells maturation (Fig. 3 and Additional file 5: 
Figure S5)
Proportion of non-conventional CD5+ B cells were not 
significantly different in rectum and blood (69.5 [66.2–
77.8] vs 75.4 [71.5–83.9], p =  0.06). Naive IgD+ B cells 
were more represented in blood versus rectum (79.01 % 
of conventional B cells [75.61–85.79] vs 35.58 % [24.37–
40.67], p  <  0.0001) and were more frequent in blood of 
“low-level CD4” group patients (82.2 [77.3–87.6] vs 
76.6  % [60.6–79.1], p  =  0.05) (Fig.  3a) and activated B 
cells IgD− were less represented (17.6 [12.4–22.4] vs 
23.1 % [20.8–38.8], p = 0.05). Proportion of IgD+ naive B 
cells conversely correlated to the current CD4+/CD8+T 
cells ratio in blood (r = −0.51, p = 0.02; Fig. 3b). Distri-
bution of memory B cells in blood was equivalent in the 
Fig. 2 Alterations in β7+ CD4+ T cells homing to the gut is higher in patients who started cART late and is conversely correlated to the decrease 
of the ratio CD4+/CD8+ T cells. Correlation between the ratio blood/rectum of β7 expression in CD4+ T cells and the number of CD4+ T cells at the 
initiation of cART (a) and with the ratio CD4+/CD8+ T cells in blood (b). Flow cytometry analysis of β7 expression in CD4+ T cells in blood and in 
rectum of two HIV‑infected individual representatives of “high” and “low‑level CD4 group” respectively (c). Gating strategy: lymphoid cells were gated 
using the FSC/SSC parameters. Then, T cells were gated by their expression of CD3 and were separated in CD4+ and CD8+ T cells by the CD4 expres‑
sion and β7expression was studied in CD4+ T cells. Each symbol represents an individual
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two groups (5.94  % of conventional B cells [1.68–18.05] 
in “high-level CD4 group” vs 4.05 % [2.07–5.66] in “low-
level CD4” group, p =  0.34). Contrary to CD4+ T cells, 
no increase of β7+ B cells in blood of “low-level CD4” 
group was observed.
Initiation of cART with high CD4 level results in a lower 
HIV-1 reservoir in blood and gut (Fig. 4)
Total HIV DNA loads in blood and rectal compartments 
were correlated (r = 0.65, p = 0.0008). The median HIV 
DNA load was not higher in rectum than in PBMCs 
(3.51 [2.81–3.96] vs 3.21 [2.44–3.65] log copies/millions 
of cells, p  =  0.24). HIV DNA loads were significantly 
higher in “low-level” than in “high-level CD4” group 
(3.48 [3.17–3.7] vs 2.41 [2.03–2.93] log copies/millions 
of cells, p = 0.002 and 3.6 [3.4–4.08] vs 3.06 [1.93–3.63] 
log copies/millions of cells, p  =  0.042 in blood and 
rectum, respectively, Fig.  4c, d). An inverse correla-
tion between the number of blood CD4+ T cells at the 
time of cART initiation and the size of HIV reservoir in 
blood (r = −0.52, p = 0.01) but not in rectum (r = −0.3, 
p = 0.15) was observed (Fig. 4b). The patients who initi-
ated cART during PHI presented a lower size of HIV res-
ervoir in blood and rectum. The presence of HIV RNA 
was detected in 15 out of 24 (62.5 %) PBMCs and in 21 
out of 24 (87.5  %) rectal biopsies, respectively. HIV-1 
DNA levels were significantly higher in rectum of patients 
exhibiting detectable HIV-1 RNA in this compartment 
(3.59 [3.34–3.99] vs 1.4 [0.85–1.76], p = 0.008). This was 
not verified in blood compartment, but the expression of 
p24 in CD4+ T cells in PBMC tended to be higher when 
the virus was detected in periphery (1.03 [0.57–1.82] vs 
Fig. 3 Repartition of naive and activated B cells in blood, according to the CD4+ T cells at the initiation of cART. Frequency of IgD+ naive B cells (a) 
in blood of HIV‑1 infected individuals, treated above or below 350 CD4+/mm3 T cells count. Horizontal lines represent median values and ranges. 
Correlation between current CD4+/CD8+ T cells ratio in blood and percentage of IgD+ naive B cells in blood of HIV infected individuals (b). Each 
symbol represents an individual. Flow cytometry analysis of IgD+/CD19+/CD5− B cells in the blood of two HIV‑infected individual representatives of 
“high” and “low‑level CD4 group” respectively (c). Gating strategy: lymphoid cells were gated using the FSC/SSC parameters. Then, B cells were gated 
by their expression of CD19 and were separated in CD5+ non‑conventional and CD5− conventional B cells. IgD expression was studied in CD5− 
conventional B cells to plot naive and activated B cells
Page 7 of 13Depincé‑Berger et al. Retrovirology  (2016) 13:44 
0.39 % of CD4+ T cells [0.34–0.8], p = 0.09). No signifi-
cant relation was observed between HIV-1 RNA detec-
tion and the ratio CD4+/CD8+ T cells, Th17/Treg ratio, 
β7 blood/rectum ratio, and PD1+ expression in T cells, in 
both compartments.
Discussion
The CD4+ T cells subset depletion is higher in gut than 
in peripheral compartment and its recovery is delayed 
and incomplete under cART [5]. In our study, we showed 
that the ratio CD4+/CD8+ T cells was higher in the blood 
than in the rectum of cART-experienced patients and 
was correlated to the CD4 count at the time of initiation 
of therapy. A persistent activated and exhausted pheno-
type of PD-1 expressing T cells in GALT has been evi-
denced, independently of the CD4 level measured at the 
time of cART initiation. The role of PD-1 is defined as a 
negative regulator of T cell function during HIV infec-
tion, and thus as an indicator of immune activation and 
disease progression. It contributes to the generation of 
activated T cell targets for the virus itself, further driving 
viral replication [28, 29].
A persistent immune activation in GALT promotes 
early and serious immunological and structural inju-
ries of the mucosal barrier favoring the translocation of 
microbial products, such as LPS, into the systemic cir-
culation [30, 31]. Th17 cells represent a CD4+ T cells 
subset involved in enterocytes homeostasis, that plays 
a critical role in the mucosal defense against bacteria 
and fungi. Those cells are preferentially depleted in the 
GALT of HIV-infected patients [6]. The median counts 
of Th17 cells were similar in the blood and in the rectum 
in our two studied groups. The role of Th17 cells is bal-
anced by Treg cells and the Th17/Treg ratio reflects the 
gut homeostasis preservation. In our study, as in others, 
the gut homeostasis was not significantly improved in 
the “high-level CD4 group”, and despite several years of 
cART, the restoration of CD4+ and Th17 cells remains 
typically incomplete, even in the four men who started 
cART during PHI [4, 32–34]. This finding is not in agree-
ment with a previous study demonstrating a preserva-
tion of mucosal Th17 function in gut of patients who 
had initiated cART very early. This can be due to dif-
ferences between the two studied populations, in terms 
Fig. 4 HIV reservoir size is lower in blood and rectum of patients who initiated cART with low number of CD4+ T cells. Correlation between HIV 
DNA loads in PBMC and rectum (a). Correlation between HIV DNA in PBMC and number of CD4+ T cells at the initiation of cART (b). Comparison 
between HIV DNA loads in PBMC (c) and rectum (d) of patients from the two groups. HIV DNA loads are expressed in log copies/million of cells. 
Horizontal lines represent median values and ranges.*p < 0.05; **p < 0.01. Each symbol represents an individual
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of size (low in our work) and Fiebig stage at the time of 
cART start (FIII vs F I/II) [27]. Interestingly, in our study, 
gut homeostasis was negatively correlated with CD8+ 
T cell exhaustion. This could participate to increase the 
immune activation, probably contributing to the vicious 
circle “immune activation–viral replication and depletion 
of activated target T cells-microbial translocation”.
Another hypothesis to explain the impairment of the 
ratio CD4+/CD8+ T cells of GALT under cART is the 
alteration of CD4+ T cell homing to the gut. The α4β7 
integrin is involved in gut homing of T cells via the 
Mucosal vascular-Addressin Cell-Adhesin Molecule 1 
(MAdCAM-1) expressed on endothelial cells in gut. The 
ability of HIV-1 gp120 to bind to and signal through α4β7 
could contribute to the tropism of HIV-1 for CD4+ T cells 
in the gut [3, 35]. As previously reported, α4β7+CD4+ T 
cells could be distinguished by high-level expression of 
integrin β7 [35]. In our study, the blood/rectum CD4+β7+ 
cells ratio reflects the alteration of gut homing CD4+ T 
cells. A later initiation of cART is significantly associated 
with a major gut homing alteration of CD4+, but not of 
other lymphocytes subsets (CD8+ T, B lymphocytes). We 
could hypothesize that this homing defect contributes to 
the CD4+ T cells deficiency in GALT. Nevertheless, this 
defect of homing was not significantly correlated with the 
decrease of the ratio CD4+/CD8+ T cells in rectum. This 
may be explained by the moderate number of patients in 
our study and by a probable peripheral α4β7 up-regula-
tion. Mavigner et  al. suggested that many of the CCR9/
α4β7 expressing-CD4+ T cells remained in the blood 
circulation rather than repopulating the gut mucosa 
because of a lower expression of the CCL25 CCR9 ligand 
in the intestine of HIV-infected individuals, whereas the 
MAdCAM-1 expression was similar in HIV-infected 
patients and healthy controls [5]. We did not confirm the 
data of a recent paper reporting an absence of depletion 
of CD4+ cells expressing gut homing markers, in blood 
and in gut of cART-experienced patients [36]. However, 
the two works are difficult to compare since studied pop-
ulations, particularly in terms of durations of infection 
and cART therapy, and methods (cells isolation, lympho-
cytes subpopulations studied) are slightly different. Inter-
estingly, it has been suggested that the expression of α4β7 
and CCR9 on activated T cells is stimulated by retinoic 
acid, a vitamin A metabolite produced by dendritic cells 
[37]. Quantifying this marker in blood could be helpful to 
evaluate the GALT homing ability of T cells.
As previously described, B cells hyperactivation by 
HIV is a common feature, characterized by hypergam-
maglobulinemia and a rapid turnover [16]. These abnor-
malities are generally reversed by cART, excepting the 
loss of memory B cells. However, it was suggested that 
an early cART initiation could partially reverse the low 
frequency of IgM+ memory B cells [38]. A similar ten-
dency with a higher percentage of IgM+ memory B cells 
in the blood of patients treated with higher CD4 count 
was also noticed. Another interesting result concerns an 
expansion of naive B cells in the blood of our “low-level 
CD4 group”, to the detriment of mature B cells, very likely 
related to the T-cells cooperation defect in “low-level 
CD4 group”. A low number of CD4+ T cells was corre-
lated to an expansion of naive B cells, that could lead to 
a production of low-specific antibodies and paucity of 
HIV-specific IgA response at mucosal sites [38].
One of the major obstacle to HIV eradication is the 
persistence of virus within infected CD4+ T cells in 
GALT and other reservoirs [39–41]. In our study, HIV 
DNA was detected and quantified in the rectum of all 
the 24 participants and for 21 of them, a persistent viral 
replication was detected, despite a controlled viraemia, 
as previously reported [42–44]. We found that patients 
who started cART early (during the PHI phase) exhib-
ited a lower-size of viral reservoir in GALT and in 
PBMC, as previously demonstrated [17]. In PTc VIS-
CONTI cohort, the benefit of an early treatment on the 
size of HIV reservoir was demonstrated [21]. Similarly, 
we found a significant lower HIV DNA gut reservoir in 
the group of men who started cART with a CD4 cells 
count over 350/mm3. In our study, a low size of viral res-
ervoir was not significantly associated to the increase of 
the ratio CD4+/CD8+ T cells or to a loss of immune acti-
vation. The limited size of our population could explain 
that but Hey-Cunningham et al. reported the same find-
ings in patients treated by HIV integrase inhibitors [45]. 
Without cART, «elite controllers» have abnormal levels 
of T cell activation despite maintaining undetectable 
viral loads, explained by HLA polymorphisms leading to 
stronger innate immune responses or lower regulatory 
T cell activity against HIV infection, both factors that 
might contribute to more-potent suppression of HIV 
replication [46]. Moreover, a persistent residual viraemia 
was reported in patients under suppressive cART, but 
the question whether it represents an active replication 
or the release of non-productive virus from the reservoir 
has not been resolved [47]. In our study, the hypothesis 
of an active replication could be suggested by the exist-
ence of a higher rectal reservoir in patients with detect-
able HIV RNA in gut. To better appreciate the size of 
the reservoir and the latent or the replicative state of the 
virus it would have been interesting to quantify the inte-
grated and 2LTR forms of the virus in peripheral blood 
and tissues.
There are several limitations in our study, concerning 
first its low statistical power due to the limited number 
of patients included, especially those treated at PHI stage. 
Moreover, it would have been very informative to assess 
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the evolution of the viral rectal reservoir in men during 
the course of HIV infection, before and after cART initia-
tion. Obviously, for ethical reasons it was not possible to 
obtain sequential biopsies in HIV infected men. Another 
important point is the time between infection and HIV 
diagnosis that is most of the time unknown but can influ-
ence the composition of the reservoir.
And finally, our study aims to explore the rectal reser-
voir and it is admitted that the distribution of HIV DNA 
and RNA in cell subsets differs in different gut compart-
ments. This might be kept in mind when interpreting the 
results but an exhaustive analysis is quite complicated, 
since the gastrointestinal tissues are not easily accessible.
Conclusions
In conclusion, our study suggests that early treatment 
partially circumvents immune dysregulation in the rec-
tum of HIV-infected men even if their CD4+ cell count 
was elevated at the time of initiation of therapy. These 
findings confirm the great interest of an initiation of 
cART in the early stages of HIV infection to limit the 
viral reservoir constitution, to preserve the gut immunity 
and, as a consequence, to improve patients outcomes and 
reduce HIV transmission at the population level.
Methods
Patients and samples
HIV-1 chronically infected consenting men followed at 
the Infectious Diseases Department of the University 
Hospital of Saint-Etienne were enrolled. They had been 
under cART for more than one but <5 years, without any 
viral escape during this period. They also had an indica-
tion for anal cancer screening by rectoscopy. For each 
patient, 2 EDTA-blood samples and 4 rectal biopsies 
were collected at the Gastroenterology Unit of the Uni-
versity Hospital of Saint-Etienne. Patients were distrib-
uted in 3 groups concerning the stage of infection at the 
time of diagnosis, according to the CDC Classification 
System for HIV Infection: A (Asymptomatic or Acute 
HIV Infection), B (Symptomatic conditions), C (AIDS-
Indicator conditions). The patient characteristics are 
summarized in Table 2.
Tissues and cells preparation (Additional file 6: Figure S6)
PBMC were isolated from whole blood samples by stand-
ard density gradient centrifugation (Lymphoprep, Axis-
Shield, Oslo, Norway), numbered and about 1 million of 
cells were stored at −80  °C until use. An immunophe-
notypical analysis was realized on the remaining fresh 
blood cells. Two out of four rectal biopsies were imme-
diately frozen at −80  °C until molecular biology test-
ing. The remaining fresh biopsies were dedicated to the 
immunophenotypical analysis and were first incubated 
in RPMI 1640 (PAA, Pasching, Austria), supplemented 
with 1 % of antibiotics (penicillin 100 U/ml and strepto-
mycin 100 µg/ml, PAA) and 10 % of fetal bovine serum 
(Sigma Aldrich, Saint-Louis, USA). Biopsies were then 
crushed immediately with a sterile scalpel and a medicon 
of 50  µm (BD Biosciences, San Jose, USA) and 1  ml of 
EDTA/Versene solution (Gibco Life technologies, Paisley, 
UK) was added to the cellular suspension to avoid aggre-
gates. A mechanical disruption and a filtration of the sus-
pension were performed with a syringe equipped with a 
30-gauge blunt-end needle (Nipro Europe, Zaventem, 
Belgium) and a sterile filter of 30  µm (BD Biosciences). 
Then, rectal cells were washed with RPMI-FCS and re-
suspended in that medium. The quantity of cells was 
determined by the automated cell counter TC10 (Biorad, 
Hercules, CA, USA), and the viability was estimated by a 
trypan blue labelling.
Immunophenotypical analysis
For each patient, an extensive immunophenotypical 
analysis of blood and rectal fresh cells was performed. T 
cells were stained with anti-CD3/VioBlue (BW264/56), 
anti-CD4/Viogreen (VIT4), anti-CD8/APC-Cyanine7 
(BW135/80) (Miltenyi Biotec, Bergisch Gladbach, Ger-
many). The CD4+ T cells/CD8+ T cells ratio was used 
to explore the immune dysregulation. Among T cells, 
regulatory cells were identified as CD25high (anti-CD25/
PC7, B1.49.9, Iotest Beckman Coulter, Brea, USA) and 
CD127low (anti-CD127/FITC, MB15-18C9, Miltenyi 
Biotec) [48]. The CCR6 (anti-CD196/APC, 11A9, BD 
Biosciences) and the CD45 RA (CD45RA/PC7, 2H4LD-
H11LDB9, Iotest Beckman Coulter) markers were used 
to characterize Th17 cells [5, 49–51]. The Th17 popula-
tion was defined as CD4+/CD45RA−/CCR6+. The Th17/
Treg ratio was calculated. The expression of β7 integrin 
and CCR9 homing intestinal markers was studied on T 
and/or B cells (anti-β7/PE, FIB504 and anti-CDw199/
APC, 112509, BD Biosciences) [5]. Different states of T 
cells maturation were characterized by anti-CD45RA/
PC7 and CCR7 (anti-CD197/FITC, 150503, BD Bio-
sciences): naive (CD45-RA+/CCR7+), central memory 
(CM, CD45-RA−/CCR7+), effector memory (EM, CD45-
RA−/CCR7−) T cells and terminal effector cells express-
ing RA (EMRA, CD45-RA+/CCR7−) [52, 53]. Exhausted 
and HIV-1 infected T cells were determined with PD-1 
(anti-CD279/APC, MIH4, BD Biosciences) and intracel-
lular HIV-p24 protein expression (anti-p24/FITC, 24-4, 
Santa Cruz Biotechnology), respectively [54, 55]. P24 
antigen staining required a permeabilization stage (BD 
Cytofix/Cytoperm, BD Biosciences). HIV co-receptors 
CXCR4 (anti-CD184/PerCP-Cy5.5, 12G5 CXCR4, BD 
Biosciences) and CCR5 (anti-CD195/APC-Cy7, 2D7/
CCR5, BD Biosciences) were also studied.
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B cells were stained with anti-CD19/VioBlue (HD37, 
DakoCytomation, Denmark) and anti-CD5/PC7 (BL1a, 
Iotest Beckman-Coulter) to distinguish conventional and 
non-conventional B cells. The phenotype of maturation 
was evaluated with anti-IgD/FITC (IADB6, Iotest Beck-
man Coulter), anti-IgM/APC (G20-127, BD Biosciences), 
anti-CD27/APC-Cy7 (M-T271, BD Biosciences) [56, 57]. 
Naïve (unswitched) (CD19+/IgD+), unswitched mem-
ory (CD19+/IgM+/CD27+) and activated (switched) 
(CD19+/IgD−) B cells were compared.
Flow cytometry analysis
Analyses were performed on a FACS Canto II (Bec-
ton–Dickinson, Franklin Lakes, NJ, USA) and data were 
analyzed using Kaluza software (Version 1.3, Beckman-
Coulter, Brea, USA). Lymphocytes were examined using 
forward/side-scatter gating. T cells and B cells were iden-
tified subsequently as CD3+ and CD19+ cells, within the 
lymphocytes population. Each tube was run until 50,000 
events were recorded or the tube was exhausted. Our 
gating strategy was based on fluorescence minus one 
technique (FMO) to determine the positivity in expres-
sion of each considered surface marker.
Total cell-associated HIV-1 DNA quantification
Total DNA was extracted from PBMCs and biopsies 
using the QIAamp DNA Mini Kit (Qiagen, Courtaboeuf, 
France). The cell-associated HIV-1 DNA was quantified 
by using Generic HIV® DNA cell protocol (Biocentric, 
Bandol, France) according to the manufacturer’s instruc-
tions. The quantification of the glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) gene was undertaken 
to estimate the amount of cells tested. The results were 
expressed in a log of HIV DNA copies per million of 
cells.
Intra-cellular HIV-1 RNA detection
Total RNA was extracted from PBMCs and biopsies 
using RNA Blood Mini Kit (Qiagen) and RNeasy (Qia-
gen), respectively. HIV-1 RNA was detected by real-time 
PCR using the Generic HIV® assays (Biocentric), accord-
ing to manufacturer’s instructions.
Table 2 Comparison of the main characteristics of HIV infected-men enrolled in the study according to their CD4+ cells 
count at the time of cART initiation
cART combined antiretroviral therapy, CDC centers for disease control and prevention, II integrase inhibitors, PHI primary HIV infection, PVL plasmatic viral load, NNRTI 
non‑nucleoside reverse transcriptase inhibitors, NRTI nucleoside reverse transcriptase inhibitors, PI protease inhibitors
Blood CD4+ T count at the time of diagnosis (cells/mm3) p value
>350 “high-level CD4 group” (n = 9) <350 “low-level CD4 group” (n = 15)
At the time of diagnosis
 Route of contamination (%)
  MSM or bisexual 100 86.7 0.51
  Heterosexual 0 13.3 0.51
 Stage CDC of HIV infection (%)
  A (PHI) 62.5 6.7 0.01
  B or C 0 40 0.05
At the time of blood and biopsy sampling
 Age, median in years [range] 48 [28.5–49.5] 53 [46–61] 0.03
 Time since diagnosis of HIV infection, median in months 
[range]
40 [27.5–105.5] 44 [26–48] 0.63
 Total time on cART, median in months [range] 34 [18.5–60] 42 [24–46] 0.68
 cART regimen (%)
  3 NRTI 100 93.3 0.009
  2 NRTI/1 NNRTI 55.5 53.3 1
  2 NRTI/1 PI 44.4 46.6 1
  2 NRTI/1 II 0 13.3 0.51
At the time of cART initiation
 Time since diagnosis of HIV infection, median in months 
[range]
2 [0.5–73.5] 0 [0–1] 0.05
 Initiation at PHI stage (%) 33.3 6.7 0.13
 CD4+ T cells/mm3, median [range] 450 [427–695] 98 [31–257] <0.0001
 PVL in log10 copies/ml, median [range] 4.97 [4.24–6.1] 5.52 [5.17–5.94] 0.25
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Statistical analysis
Statistical analysis was performed using Prism Graph-
Pad version 5 Software (GraphPad Prism, San Diego, 
CA, USA). Medians and interquartile ranges (IQR) were 
used to represent the average values. The non-paramet-
ric Mann–Whitney test and Chi-square test were used 
to determine the significance of differences between the 
two groups. The correlation between the level of CD4+ 
T cells at the beginning of cART and the immunological 
and virological characteristics of reservoirs was analyzed 
using the Spearman correlation test. A p value <0.05 was 
considered to be statistically significant.
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